enVVeno Medical (NVNO)
NASDAQ:NVNO
NVNO Stock Chart & Stats
$0.36
-$0.06(-1.92%)
At close: 4:00 PM EST
$0.36
-$0.06(-1.92%)
Day’s Range― - ―
52-Week Range$8.67 - $196.70
Previous CloseN/A
Volume33.14K
Average Volume (3M)589.93K
Market Cap
$6.89M
Enterprise Value-$2.19M
Total Cash (Recent Filing)$28.21M
Total Debt (Recent Filing)$700.00K
Price to Earnings (P/E)―
Beta1.82
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding655,606
10 Day Avg. Volume395,892
30 Day Avg. Volume589,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.89
Enterprise Value/Ebitda0.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-35
Revenue Forecast (FY)$7.00M
Bulls Say, Bears Say
Bulls Say
Differentiated Product PlatformenVVeno’s VenoValve is a specialized, implantable bioprosthetic designed to restore femoral vein valve function. A durable, device-led solution targeting chronic venous insufficiency addresses a clear clinical unmet need and can create product differentiation and regulatory pathway-driven barriers to entry if clinical/commercial execution succeeds.
Low Financial LeverageThe company’s very low debt-to-equity (~0.03 and declining) materially reduces near-term solvency risk and interest burden. Structurally, low leverage provides flexibility to fund additional R&D or regulatory milestones without immediate refinancing pressure, supporting execution on device development over the next several quarters.
Cash Runway And Listing StabilityRegaining Nasdaq compliance removes immediate listing risk and the reported ~$28M in cash/investments supports 2026 strategic plans. Together these durable factors improve visibility with investors and provide a runway to advance clinical and commercialization milestones before additional financing is required.
Bears Say
No RevenueAcross 2020–2025 the company reports zero revenue, meaning the business model remains unproven commercially. Without demonstrable sales, the firm depends on future clinical success and market adoption; this structural gap elevates execution risk and extends reliance on external funding until commercialization.
Persistent Cash BurnConsistent operating and free cash outflows (~$12M–$19M annually) create ongoing funding dependence. Persistently negative cash generation forces serial capital raises or dilution risk, constrains strategic optionality, and raises sustainability concerns absent material revenue or expense reductions.
Eroding Equity And Negative ReturnsEquity declining materially over 2021–2025 and deeply negative ROE reflect cumulative losses consuming shareholder capital. This structural erosion reduces financial flexibility to pursue growth, weakens the balance sheet cushion for setbacks, and signals the company is not yet generating returns on invested capital.
enVVeno Medical News
NVNO FAQ
What was enVVeno Medical’s price range in the past 12 months?
enVVeno Medical lowest stock price was $8.67 and its highest was $196.70 in the past 12 months.
What is enVVeno Medical’s market cap?
enVVeno Medical’s market cap is $6.89M.
When is enVVeno Medical’s upcoming earnings report date?
enVVeno Medical’s upcoming earnings report date is May 04, 2026 which is in 38 days.
How were enVVeno Medical’s earnings last quarter?
Currently, no data Available
Is enVVeno Medical overvalued?
According to Wall Street analysts enVVeno Medical’s price is currently Overvalued.
Does enVVeno Medical pay dividends?
enVVeno Medical does not currently pay dividends.
What is enVVeno Medical’s EPS estimate?
enVVeno Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does enVVeno Medical have?
enVVeno Medical has 655,606 shares outstanding.
What happened to enVVeno Medical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of enVVeno Medical?
Currently, no hedge funds are holding shares in NVNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
enVVeno Medical
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.